Trinity Biotech Appoints Paul Tivnan as Non-Executive Director
Trinity Biotech (Nasdaq: TRIB), a commercial-stage biotechnology company specializing in human diagnostics and diabetes management solutions, has appointed Paul Tivnan as a Non-Executive Director to its Board of Directors. Tivnan brings over 25 years of senior leadership experience in finance, capital markets, and corporate governance.
Currently serving as CFO of Deriva Energy LLC, Tivnan's notable experience includes leading Ardmore Shipping Corporation's NYSE IPO in 2013 as CFO. He holds multiple professional qualifications including being a Fellow of the Institute of Chartered Accountants of Ireland and a Certified International Director from INSEAD Business School.
The appointment aligns with Trinity Biotech's transformation strategy and focus on growth in diagnostics and wearable health technologies.
Trinity Biotech (Nasdaq: TRIB), azienda biotech in fase commerciale specializzata in diagnostica umana e soluzioni per la gestione del diabete, ha nominato Paul Tivnan come Direttore Non Esecutivo nel suo Consiglio di Amministrazione. Tivnan vanta oltre 25 anni di esperienza dirigenziale in ambito finanziario, mercati dei capitali e governance aziendale.
Attualmente CFO di Deriva Energy LLC, tra i suoi ruoli significativi si segnala la guida dell'IPO alla NYSE di Ardmore Shipping Corporation nel 2013 in qualità di CFO. Possiede diverse qualifiche professionali, tra cui la Fellowship dell'Institute of Chartered Accountants of Ireland e il titolo di Certified International Director presso INSEAD Business School.
La nomina è coerente con la strategia di trasformazione di Trinity Biotech e con l'obiettivo di crescere nei settori della diagnostica e delle tecnologie indossabili per la salute.
Trinity Biotech (Nasdaq: TRIB), compañía biotecnológica en fase comercial especializada en diagnóstico humano y soluciones para la gestión de la diabetes, ha nombrado a Paul Tivnan como Director No Ejecutivo de su Junta Directiva. Tivnan aporta más de 25 años de experiencia en puestos sénior en finanzas, mercados de capital y gobierno corporativo.
Actualmente es CFO de Deriva Energy LLC; entre sus hitos destaca liderar la OPV en la NYSE de Ardmore Shipping Corporation en 2013 como CFO. Cuenta con diversas acreditaciones profesionales, entre ellas Fellow del Institute of Chartered Accountants of Ireland y Certified International Director por INSEAD Business School.
El nombramiento encaja con la estrategia de transformación de Trinity Biotech y su enfoque en el crecimiento en diagnóstico y tecnologías de salud vestibles.
Trinity Biotech (Nasdaq: TRIB)는 인체 진단 및 당뇨 관리 솔루션을 전문으로 하는 상업 단계 바이오텍 회사로, 이사회에 비집행이사로 Paul Tivnan을 선임했습니다. Tivnan은 금융, 자본시장 및 기업 지배구조 분야에서 25년 이상의 고위 경력을 보유하고 있습니다.
현재 Deriva Energy LLC의 CFO로 재직 중인 그는 2013년 Ardmore Shipping Corporation의 NYSE 상장(IPO)을 CFO로 이끈 경력이 있습니다. 아일랜드 공인회계사연맹(Fellow of the Institute of Chartered Accountants of Ireland) 및 INSEAD 비즈니스스쿨의 Certified International Director 등 여러 전문 자격을 보유하고 있습니다.
이번 선임은 Trinity Biotech의 전환 전략과 진단 및 웨어러블 헬스 기술 분야 성장에 대한 집중과 일치합니다.
Trinity Biotech (Nasdaq: TRIB), société biotechnologique en phase commerciale spécialisée dans le diagnostic humain et les solutions de gestion du diabète, a nommé Paul Tivnan au poste d'administrateur non exécutif au sein de son conseil d'administration. Tivnan apporte plus de 25 ans d'expérience à des postes de direction dans la finance, les marchés de capitaux et la gouvernance d'entreprise.
Actuellement directeur financier de Deriva Energy LLC, il a notamment piloté l'introduction en bourse d'Ardmore Shipping Corporation à la NYSE en 2013 en tant que CFO. Il détient plusieurs qualifications professionnelles, dont la fellowship de l'Institute of Chartered Accountants of Ireland et le titre de Certified International Director de l'INSEAD Business School.
Cette nomination s'inscrit dans la stratégie de transformation de Trinity Biotech et son objectif de croissance dans le diagnostic et les technologies de santé portables.
Trinity Biotech (Nasdaq: TRIB), ein kommerzielles Biotechnologieunternehmen, das sich auf humanmedizinische Diagnostik und Diabetes-Management-Lösungen spezialisiert hat, hat Paul Tivnan als Non-Executive Director in den Vorstand berufen. Tivnan verfügt über mehr als 25 Jahre Führungserfahrung in den Bereichen Finanzen, Kapitalmärkte und Unternehmensführung.
Derzeit als CFO von Deriva Energy LLC tätig, führte er 2013 als CFO den Börsengang (IPO) von Ardmore Shipping Corporation an der NYSE. Er besitzt mehrere berufliche Qualifikationen, darunter Fellow des Institute of Chartered Accountants of Ireland und Certified International Director der INSEAD Business School.
Die Berufung steht im Einklang mit Trinity Biotechs Transformationsstrategie und dem Fokus auf Wachstum in der Diagnostik und bei tragbaren Gesundheitstechnologien.
- Addition of extensive capital markets and operational leadership experience to the Board
- Strategic alignment with company's transformation and growth initiatives in diagnostics and wearable technologies
- Enhanced corporate governance through diverse, international perspective
- None.
DUBLIN, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Paul Tivnan to its Board of Directors as a Non-Executive Director.
Mr. Tivnan brings over 25 years of senior leadership experience in finance, capital markets, and corporate governance across the infrastructure, energy, shipping, and cleantech sectors. He currently serves as Chief Financial Officer of Deriva Energy LLC, one of the largest independent renewable power producers in the United States and a Brookfield portfolio company. His previous roles include CFO of Brookfield Renewable Ireland and CFO of Ardmore Shipping Corporation, where he led the company’s successful IPO on the New York Stock Exchange in 2013. Mr. Tivnan has also served as a Director of Element 1 Corp, a developer of advanced hydrogen technologies.
John Gillard, President and Chief Executive Officer of Trinity Biotech, commented: “We are delighted to welcome Paul to the Board. His extensive experience in capital markets and operational leadership across large scale global sectors will be invaluable to our company as we continue to execute our transformation strategy and pursue growth opportunities in diagnostics and wearable health technologies. Paul’s appointment reflects our commitment to strengthening our corporate governance and bringing diverse, high-impact and international perspectives to the Board, as Trinity Biotech continues to transform and develop.”
Mr. Tivnan is a Certified International Director from INSEAD Business School and has completed executive leadership and corporate governance programs at INSEAD and London Business School. Earlier in his career, Mr. Tivnan worked at Ernst & Young in Financial Services Advisory, specializing in international tax and corporate structuring. He holds a B.A. degree in Accounting and Finance and a Master of Business Studies degree from Dublin City University. He is a Fellow of the Institute of Chartered Accountants of Ireland, a Chartered Tax Advisor, and a member of the Institute of Chartered Shipbrokers.
Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.
| Contact: | Trinity Biotech plc | RedChip Companies Inc. |
| Susan O’Connor | Dave Gentry, CEO | |
| (353)-1-2769800 | (1)-407-644-4256 | |
| (1)-800-RED-CHIP (733-2447) | ||
| TRIB@redchip.com |
FAQ
Who is Paul Tivnan and what is his role at Trinity Biotech (TRIB)?
What is Paul Tivnan's professional background before joining Trinity Biotech's board?
What are Paul Tivnan's qualifications and certifications?
How will Paul Tivnan's appointment benefit Trinity Biotech (TRIB)?
